3.82 (-%)
As of Oct 13, 2023
Source:
We are a clinical-stage biopharmaceutical company engaged in the science of ribosome modulation, leveraging both our innovative TURBO-ZM chemistry technology platform and our library of novel aminoglycosides in an effort to develop novel oral small molecule Ribosome Modulating Agents (RMAs) and Eukaryotic Ribosome Selective Glycosides (ERSGs), for the treatment of rare and ultra-rare premature stop codon diseases and ribosomal mutations.
Country | United States |
Headquarters | watertown, massachusetts |
Phone Number | 781-577-5300 |
Industry | services |
CEO | Sumit Aggarwal |
Website | www.eloxxpharma.com |